GLP-1 MEDICATION: QUICK FIX OR LONG-LASTING SOLUTION?

The Role of Fitness, Physical Activity and Exercise in Supporting GLP-1 Users for Sustainable Health Outcomes

The rapid expansion of GLP-1 therapies is reshaping the obesity and health landscape across Europe, raising important questions about long term effectiveness, equity and sustainability. This paper sets out a clear case for embedding physical activity alongside pharmacological treatment as part of a whole system approach that also includes nutrition and mental health support, with the aim of delivering sustainable health outcomes.

Developed in collaboration with Havas, the paper is designed as a practical resource for policymakers, health professionals, employers, insurers, industry stakeholders and the wider health and physical activity sector. It can be used to inform internal discussions, support external communications, and contribute to evidence based engagement with stakeholders on the role of physical activity in obesity management. Readers are encouraged to share the paper within their networks, reference it in professional discussions, and use it to stimulate informed debate on how GLP-1 therapies can be integrated more effectively into prevention and treatment pathways.